vs
Farmland Partners Inc.（FPI）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Farmland Partners Inc.的1.7倍（$35.5M vs $20.7M），Farmland Partners Inc.净利率更高（103.4% vs -304.2%，领先407.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -3.5%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 31.4%）
农场土地工业曾是北美规模最大的农业合作社，在2002年至2004年间完成了全部资产出售。在其74年的经营历史中，该合作社作为多元化综合型机构为农户会员提供服务，在北美本土及全球农业市场都发挥过重要作用。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FPI vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.7倍
$20.7M
营收增速更快
RXRX
高出685.3%
-3.5%
净利率更高
FPI
高出407.7%
-304.2%
两年增速更快
RXRX
近两年复合增速
31.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $35.5M |
| 净利润 | $21.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 103.4% | -304.2% |
| 营收同比 | -3.5% | 681.7% |
| 净利润同比 | -63.5% | 39.6% |
| 每股收益（稀释后） | $0.44 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FPIRXRX
| Q4 25 | $20.7M | $35.5M | ||
| Q3 25 | $11.3M | $5.2M | ||
| Q2 25 | $10.0M | $19.2M | ||
| Q1 25 | $10.3M | $14.7M | ||
| Q4 24 | $21.5M | $4.5M | ||
| Q3 24 | $13.3M | $26.1M | ||
| Q2 24 | $11.4M | $14.4M | ||
| Q1 24 | $12.0M | $13.8M |
净利润FPIRXRX
| Q4 25 | $21.4M | $-108.1M | ||
| Q3 25 | $483.0K | $-162.3M | ||
| Q2 25 | $7.6M | $-171.9M | ||
| Q1 25 | $2.0M | $-202.5M | ||
| Q4 24 | $58.7M | $-178.9M | ||
| Q3 24 | $1.8M | $-95.8M | ||
| Q2 24 | $-2.0M | $-97.5M | ||
| Q1 24 | $1.4M | $-91.4M |
毛利率FPIRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率FPIRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | 4.3% | -3327.6% | ||
| Q2 25 | 78.2% | -916.8% | ||
| Q1 25 | 20.6% | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | 13.9% | -377.1% | ||
| Q2 24 | -17.9% | -697.4% | ||
| Q1 24 | 11.9% | -698.4% |
净利率FPIRXRX
| Q4 25 | 103.4% | -304.2% | ||
| Q3 25 | 4.3% | -3135.3% | ||
| Q2 25 | 76.3% | -894.2% | ||
| Q1 25 | 19.9% | -1373.3% | ||
| Q4 24 | 273.6% | -3935.5% | ||
| Q3 24 | 13.5% | -367.5% | ||
| Q2 24 | -17.5% | -676.6% | ||
| Q1 24 | 11.5% | -662.4% |
每股收益（稀释后）FPIRXRX
| Q4 25 | $0.44 | $-0.17 | ||
| Q3 25 | $0.00 | $-0.36 | ||
| Q2 25 | $0.14 | $-0.41 | ||
| Q1 25 | $0.03 | $-0.50 | ||
| Q4 24 | $1.09 | $-0.56 | ||
| Q3 24 | $0.02 | $-0.34 | ||
| Q2 24 | $-0.06 | $-0.40 | ||
| Q1 24 | $0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $161.6M | $9.6M |
| 股东权益账面价值 | $467.4M | $1.1B |
| 总资产 | $719.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.35× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FPIRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务FPIRXRX
| Q4 25 | $161.6M | $9.6M | ||
| Q3 25 | $170.4M | $11.9M | ||
| Q2 25 | $193.4M | $14.2M | ||
| Q1 25 | $202.6M | $16.4M | ||
| Q4 24 | $204.6M | $19.0M | ||
| Q3 24 | $394.0M | $20.5M | ||
| Q2 24 | $393.0M | $22.9M | ||
| Q1 24 | $383.0M | — |
股东权益FPIRXRX
| Q4 25 | $467.4M | $1.1B | ||
| Q3 25 | $457.3M | $1.0B | ||
| Q2 25 | $473.5M | $919.1M | ||
| Q1 25 | $492.2M | $933.9M | ||
| Q4 24 | $494.6M | $1.0B | ||
| Q3 24 | $519.4M | $524.6M | ||
| Q2 24 | $521.5M | $584.4M | ||
| Q1 24 | $526.7M | $401.2M |
总资产FPIRXRX
| Q4 25 | $719.1M | $1.5B | ||
| Q3 25 | $738.5M | $1.4B | ||
| Q2 25 | $776.7M | $1.3B | ||
| Q1 25 | $810.5M | $1.3B | ||
| Q4 24 | $869.6M | $1.4B | ||
| Q3 24 | $1.0B | $726.5M | ||
| Q2 24 | $1.0B | $775.9M | ||
| Q1 24 | $1.0B | $557.8M |
负债/权益比FPIRXRX
| Q4 25 | 0.35× | 0.01× | ||
| Q3 25 | 0.37× | 0.01× | ||
| Q2 25 | 0.41× | 0.02× | ||
| Q1 25 | 0.41× | 0.02× | ||
| Q4 24 | 0.41× | 0.02× | ||
| Q3 24 | 0.76× | 0.04× | ||
| Q2 24 | 0.75× | 0.04× | ||
| Q1 24 | 0.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 0.81× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FPIRXRX
| Q4 25 | $17.4M | $-46.1M | ||
| Q3 25 | $-2.0M | $-117.4M | ||
| Q2 25 | $-2.2M | $-76.4M | ||
| Q1 25 | $6.4M | $-132.0M | ||
| Q4 24 | $16.1M | $-115.4M | ||
| Q3 24 | $-4.3M | $-59.2M | ||
| Q2 24 | $-6.1M | $-82.2M | ||
| Q1 24 | $11.9M | $-102.3M |
自由现金流FPIRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率FPIRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度FPIRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率FPIRXRX
| Q4 25 | 0.81× | — | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.66× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
